APA

Goldberg S. B., Schalper K. A., Gettinger S. N., Mahajan A., Herbst R. S., Chiang A. C., Lilenbaum R., Wilson F. H., Omay S. B., Yu J. B., Jilaveanu L., Tran T., Pavlik K., Rowen E., Gerrish H., Komlo A., Gupta R., Wyatt H., Ribeiro M., Kluger Y., Zhou G., Wei W., Chiang V. L. & Kluger H. M. (20200709). Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. : The Lancet. Oncology.

Chicago

Goldberg Sarah B, Schalper Kurt A, Gettinger Scott N, Mahajan Amit, Herbst Roy S, Chiang Anne C, Lilenbaum Rogerio, Wilson Frederick H, Omay Sacit Bulent, Yu James B, Jilaveanu Lucia, Tran Thuy, Pavlik Kira, Rowen Elin, Gerrish Heather, Komlo Annette, Gupta Richa, Wyatt Hailey, Ribeiro Matthew, Kluger Yuval, Zhou Geyu, Wei Wei, Chiang Veronica L and Kluger Harriet M. 20200709. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. : The Lancet. Oncology.

Harvard

Goldberg S. B., Schalper K. A., Gettinger S. N., Mahajan A., Herbst R. S., Chiang A. C., Lilenbaum R., Wilson F. H., Omay S. B., Yu J. B., Jilaveanu L., Tran T., Pavlik K., Rowen E., Gerrish H., Komlo A., Gupta R., Wyatt H., Ribeiro M., Kluger Y., Zhou G., Wei W., Chiang V. L. and Kluger H. M. (20200709). Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. : The Lancet. Oncology.

MLA

Goldberg Sarah B, Schalper Kurt A, Gettinger Scott N, Mahajan Amit, Herbst Roy S, Chiang Anne C, Lilenbaum Rogerio, Wilson Frederick H, Omay Sacit Bulent, Yu James B, Jilaveanu Lucia, Tran Thuy, Pavlik Kira, Rowen Elin, Gerrish Heather, Komlo Annette, Gupta Richa, Wyatt Hailey, Ribeiro Matthew, Kluger Yuval, Zhou Geyu, Wei Wei, Chiang Veronica L and Kluger Harriet M. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. : The Lancet. Oncology. 20200709.